Patheon sells off its Mexican division for $34M

Contract drug developer Patheon has flipped its Mexican operations to Perrigo ($PRGO) for $34 million in cash, shifting its focus to the U.S. and Europe. Under the deal, Perrigo gets Patheon's softgel manufacturing and formulation capacity in Mexico. Patheon, part of the DPx conglomerate, has been investing elsewhere in North America, this week spending about $3 million to expand a North Carolina testing facility. Sale | Expansion

Suggested Articles

Data firm Syapse has begun working with the FDA to help bring real-world evidence to bear on the agency’s decisions to approve cancer drugs.

The People-Centered Research Foundation tapped Datavant to de-identify real-world data across its national clinical research network.

Boehringer Ingelheim and MD Anderson Cancer Center have joined forces to create a “virtual” R&D hub so the pair can work on cancer drugs.